Metformin, Careprost, Sildenafil, Tadalafil

All product prices are in US dollars.
US Brand Name Genevac-B
Generic Name Hepatitis B Virus surface antigen, recombinant
Other Brand Name Genevac-B
Packing 1
Manufacturer Sanofi Aventis
Form Vial
Strength 0.5ml

  • 20 mcg 10 ml Vial $42.18
Available online
More Views

Similar Product

  • Tritanrix HB Inj

    Generic Name:Diphtheria toxoid/ Hepatitis B surface antigen (recombinant)/ Pertussis antigens/ Tetanus toxoid
    Out of Stock
  • Twinrix Syringe

    Generic Name:Hepatitis A virus, Hepatitis B virus surface antigen
    Out of Stock
  • Engerix-B Hepatitis B Vaccine

    Generic Name:Hepatitis B surface Antigen (Recombinant)
    Out of Stock
  • Havrix Injection

    Generic Name:Hepatitis A Virus
    Out of Stock
  • Hepatect CP Injection

    Generic Name: Human Hepatitis-B Immunoglobulin
    Form: Vial
  • Hepatitis-B Imm.Globulin Vaccine Injection

    Generic Name: Human hepatitis B Ig
    Form: Syringe
    Out of Stock
  • iCare Hepatitis C Test Kit

    Generic Name: iCare Hepatitis C Test Kit
    Form: Testkit
    Out of Stock
< >

1 1 1 1 1 1 1



Hepatitis B Virus surface antigen is a vaccine containing a hepatitis B antigen (HBsAg) and does not contain live germs and is used to prevent hepatitis B.


Shake the syringe before use, warm to room temperature if necessary. The injection should be administered intramuscularly (into the deltoid muscle in adults and children in the thigh in infants). In some cases (hemophilia, low platelets), the injection can be performed by subcutaneous injection.

Side effects

Reactions as pain, redness, lump at the injection site. Rare: mild fever for 1 or 2 days, headache, dizziness, fatigue, malaise, tingling in extremities, muscle or joint pain, digestive disorders, itching, rash. Exceptional: An allergic reaction. Neurological disorders (including multiple sclerosis) were rarely observed after vaccination against hepatitis B vaccine responsibility in the occurrence of these disorders is not established until now as a precautionary measure, vaccination should be considered only in people with multiple sclerosis when the risk of hepatitis B is important. Indeed, stimulating the immune system represented by this vaccine may interfere with autoimmune disease. Febrile reactions due to vaccines may be reduced by taking aspirin or paracetamol Hepatitis B Virus surface antigen, recombinant.


This vaccine should not be used in cases of known allergy to any component of the vaccine, or allergic reaction to an injection that took place earlier with the same vaccine.


To maintain effectiveness, this drug should be stored between +2 degree C to +8 degree C (the coldest part of the refrigerator). However, a break in the cold chain for a limited period of time (several hours at room temperature below 25 degree C) should not lead to a result. In practice, if necessary, a few hours can separate purchase of vaccine, the pharmacy store in refrigerator or vaccination. This vaccine should not be frozen.


Hepatitis B Virus Surface Antigen Recombinant 20 mcg / 0.5 ml.

Important Precautions

In case of high fever, acute illness, it is preferable to postpone vaccination. Before the third injection, the antibody may be insufficient and prevention (including condoms) should be used in contact with persons infected with hepatitis B. This vaccine does not protect against hepatitis A, C or E or against other viruses can cause hepatitis. The people on dialysis or suffering from a deficient immune system, additional booster injections may be necessary. As with all vaccines, exceptional cases of severe allergic reactions were observed, requiring, therefore, the need for vaccination in health care where emergency treatment can be undertaken without delay.

Dosage and administration

Adults and children over 2 months: two injections one month, followed by the third 5-12 months after the second. Teenagers 10 to 15 years, it is possible to make only two injections six months apart. Another method of vaccination could also be offered to adults, when the immunity must be obtained quickly: three injections one month apart, followed by a fourth dose one year later. Booster: beyond the initial injections, reminders of vaccine against hepatitis B are reserved for situations of risk: health professionals, occupational exposure to injury, living in endemic areas or in certain communities (including psychiatric) for example. In these cases, a determination of antibodies against hepatitis B (anti-HBs) is produced. If the rate is higher than 10 mIU / ml, immunity is considered final. If the rate is less than 10 mIU / ml, a booster dose of vaccine is used, followed by another test will evaluate the merits of renewing blood. The physician should administer the injection without exceeding a total of 6 (first injection included).